3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
21
Neoplasms
13
Breast Neoplasms
8
Lung Neoplasms
6
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Lymphoma
3
Recurrence
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcopenia
1
Rectal Neoplasms
1
Quality of Life
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neurocognitive Disorders
1
Neoplasms, Plasma Cell
1
Muscular Atrophy
1
Melanoma
1
Interventions
Cisplatin
15
pembrolizumab
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
10
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Paclitaxel
7
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
Exercise
×
90 days
×
Clear all
No trials found.